Navigation Links
Refractory Hematological Malignances Treatment Opportunities Discussed in MP Advisors Report Published at

London, UK (PRWEB) September 12, 2013

Recently, cancer treatment has witnessed considerable breakthroughs in terms of the development of innovative drug products. The success in clinical research in this therapeutic area and growth in investments are attributed to positive clinical data and regulatory approvals, expanding partnerships and mergers and acquisitions (M&A) activity.

Some companies that have already scored a success in the development of novel technology platforms and drugs to treat relapsed and refractory multiple myeloma (RRMM), are expected to follow a similar scenario to unfold in the treatment of recurrent/refractory MDS (RR-MDS, High-Risk MDS) and AML (relapsed/ refractory AML, R/R AML).

Insightful research report “Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics” worked out by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics
Published: August, 2013
Pages: 37
Price:    US$ 2,500.00

The report offers an insightful overview of the approved therapies for MDS and AML, discusses the unmet needs as well as limitations of the current standard of care (SOC) for relapsed and refractory patients. The study examines commercial opportunities in purchasing the therapy area, evaluates the competitive pressure in the sphere; makes up a comprehensive list of drugs (both early-stage and late-stage) in the clinic, and also uncovers data on their mechanism of action and companies developing them; besides profiling the leading companies. The report presents a review of the recent mergers and acquisitions in the area; covers products available for in-licensing; discusses the major trends and issues related to the therapeutic area.

Report Scope:

  •     Insightful overview of the disease and a detailed discussion of the unmet needs.
  •     Vital information on the drugs in pipeline including mechanism of action (MoA) and clinical stage of development.
  •     Review of the key milestones.
  •     Data on the launch timeline and commercial opportunity of late-stage pipeline (RR MDS and RR AML).
  •     Extensive overview of the mergers and acquisitions and licensing deals over the past five years.
  •     Evaluation of the in-licensing and/or mergers and acquisitions opportunity.
  •     Description of the competitive scenario and detailed profiles of companies, including their clinical drug data, milestones and valuation.

More insightful research reports by MP Advisors can be found at

About Us: is a multilingual hypermarket offering a rich collection of comprehensive studies on various markets, sectors, industries, companies, etc. We perform professional services aimed to equip our clients with high-quality research products and support critical decision-making.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
2. Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at
3. Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
4. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
5. Clinical insight improves treatment with new lung cancer drug
6. Rapid Asthma Treatment in ER May Prevent Admission
7. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. Mobile Stroke Units Might Trim Time to Treatment
11. Breast Cancer Treatment Side Effects May Last for Years
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... ) has focused on providing comprehensive solutions involving adult stem cell therapies to ... has officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software helps practice ... an agreement between the practice owner and the patient that automatically manages all ... projections. Click here to learn more. , According to ...
(Date:11/24/2015)... ... 2015 , ... New patients who wish to seek treatment for missing teeth ... at her Mississauga, ON practice. Dr. Williams has been providing dental service for over ... , Missing teeth can lead to a variety of complications if they are not ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... launched their Black Friday sale a week early, offering 40% off select bras ... the intimate apparel industry through both mobile fit technology and the latest fashion, ...
(Date:11/24/2015)... ... November 24, 2015 , ... DMG Productions announced that they will feature ... quarter 2016 via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is ... the business of producing and supplying medical marijuana pursuant to the Marijuana for Medical ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- The hope of bearing a child ... cycles. After failure of over 15 IVF cycles, Mrs. ... hopes that she would be able to conceive ever. But finally optimism prevailed as she ... of over 15 IVF cycles. India ... one last attempt with Gaudium IVF Center in New ...
(Date:11/24/2015)...  Thanks to a donor with a personal connection ... Sister Diane Grassilli Center for Women,s Health now offers ... San Francisco . Fred Ruhland ... a gift of $617,320 that allowed the Center to ... and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography for ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
Breaking Medicine Technology: